ZA200902941B - Crystalline forms of aliskiren hemifumarate - Google Patents
Crystalline forms of aliskiren hemifumarateInfo
- Publication number
- ZA200902941B ZA200902941B ZA200902941A ZA200902941A ZA200902941B ZA 200902941 B ZA200902941 B ZA 200902941B ZA 200902941 A ZA200902941 A ZA 200902941A ZA 200902941 A ZA200902941 A ZA 200902941A ZA 200902941 B ZA200902941 B ZA 200902941B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline forms
- aliskiren hemifumarate
- hemifumarate
- aliskiren
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06123642 | 2006-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200902941B true ZA200902941B (en) | 2010-03-31 |
Family
ID=37907983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200902941A ZA200902941B (en) | 2006-11-07 | 2009-04-29 | Crystalline forms of aliskiren hemifumarate |
Country Status (25)
Country | Link |
---|---|
US (1) | US8119841B2 (de) |
EP (1) | EP2079463A1 (de) |
JP (1) | JP2010508370A (de) |
KR (1) | KR20090083918A (de) |
CN (1) | CN101594857B (de) |
AR (1) | AR063560A1 (de) |
AU (1) | AU2007323465B2 (de) |
BR (1) | BRPI0718546A2 (de) |
CA (1) | CA2668828A1 (de) |
CL (1) | CL2007003194A1 (de) |
CO (1) | CO6180428A2 (de) |
EC (1) | ECSP099385A (de) |
GT (1) | GT200900116A (de) |
IL (1) | IL198470A0 (de) |
MA (1) | MA30921B1 (de) |
MX (1) | MX2009004885A (de) |
MY (1) | MY148758A (de) |
NO (1) | NO20092102L (de) |
NZ (1) | NZ577320A (de) |
PE (2) | PE20081157A1 (de) |
RU (1) | RU2466982C2 (de) |
TN (1) | TN2009000174A1 (de) |
TW (1) | TW200827326A (de) |
WO (1) | WO2008061622A1 (de) |
ZA (1) | ZA200902941B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120029083A1 (en) * | 2007-11-13 | 2012-02-02 | Teva Pharmaceutical Industries, Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
KR101579993B1 (ko) | 2008-01-23 | 2015-12-23 | 노파르티스 아게 | 이마티닙을 이용한 티로신 키나제 수용체 kit에 의해 매개되는 증식성 질환의 치료를 최적화하는 방법 |
EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
KR20110096584A (ko) * | 2008-12-18 | 2011-08-30 | 노파르티스 아게 | 1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염 |
WO2010089105A2 (en) | 2009-02-05 | 2010-08-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Moisture-activated granulation process |
CA2724152A1 (en) * | 2009-02-05 | 2010-08-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of aliskiren compounds |
US20120220663A1 (en) * | 2009-09-03 | 2012-08-30 | Teva Pharmaceuticals Usa, Inc. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
CN102617392B (zh) * | 2011-01-28 | 2015-04-01 | 博瑞生物医药技术(苏州)有限公司 | 一种阿利克仑半富马酸盐晶型ⅰ的制备方法 |
ITMI20111290A1 (it) * | 2011-07-11 | 2013-01-12 | Djada Pharmaceutical Sa | Aliskiren emifumarato, forma cristallina e solido amorfo |
ITMI20111291A1 (it) * | 2011-07-11 | 2013-01-12 | Djada Pharmaceutical Sa | Aliskiren emifumarato etil acetato solvato |
CN103172533B (zh) * | 2011-12-20 | 2016-05-04 | 博瑞生物医药(苏州)股份有限公司 | 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途 |
JP6007096B2 (ja) * | 2011-12-28 | 2016-10-12 | エルメッド エーザイ株式会社 | 安定化カンデサルタンシレキセチル含有物の製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
AU2001273763B2 (en) * | 2000-07-05 | 2006-07-13 | Speedel Pharma Ag | Process for the preparation of substituted octanoyl amides |
BR0310084A (pt) * | 2002-05-17 | 2005-02-15 | Novartis Ag | Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético |
PE20142101A1 (es) * | 2004-03-17 | 2014-12-27 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
GB0419361D0 (en) * | 2004-08-31 | 2004-10-06 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-05 KR KR1020097011654A patent/KR20090083918A/ko not_active Application Discontinuation
- 2007-11-05 MX MX2009004885A patent/MX2009004885A/es active IP Right Grant
- 2007-11-05 CN CN2007800492907A patent/CN101594857B/zh not_active Expired - Fee Related
- 2007-11-05 RU RU2009121651/04A patent/RU2466982C2/ru not_active IP Right Cessation
- 2007-11-05 CA CA002668828A patent/CA2668828A1/en not_active Abandoned
- 2007-11-05 AU AU2007323465A patent/AU2007323465B2/en not_active Ceased
- 2007-11-05 JP JP2009535613A patent/JP2010508370A/ja active Pending
- 2007-11-05 EP EP07856175A patent/EP2079463A1/de not_active Withdrawn
- 2007-11-05 MY MYPI20091725A patent/MY148758A/en unknown
- 2007-11-05 US US12/312,320 patent/US8119841B2/en not_active Expired - Fee Related
- 2007-11-05 AR ARP070104914A patent/AR063560A1/es not_active Application Discontinuation
- 2007-11-05 PE PE2007001518A patent/PE20081157A1/es not_active Application Discontinuation
- 2007-11-05 WO PCT/EP2007/009573 patent/WO2008061622A1/en active Application Filing
- 2007-11-05 PE PE2012000369A patent/PE20121179A1/es not_active Application Discontinuation
- 2007-11-05 NZ NZ577320A patent/NZ577320A/en not_active IP Right Cessation
- 2007-11-05 BR BRPI0718546-4A patent/BRPI0718546A2/pt not_active IP Right Cessation
- 2007-11-06 CL CL200703194A patent/CL2007003194A1/es unknown
- 2007-11-06 TW TW096141915A patent/TW200827326A/zh unknown
-
2009
- 2009-04-29 ZA ZA200902941A patent/ZA200902941B/xx unknown
- 2009-04-30 IL IL198470A patent/IL198470A0/en unknown
- 2009-05-05 TN TNP2009000174A patent/TN2009000174A1/fr unknown
- 2009-05-06 GT GT200900116A patent/GT200900116A/es unknown
- 2009-05-27 MA MA31922A patent/MA30921B1/fr unknown
- 2009-05-28 NO NO20092102A patent/NO20092102L/no not_active Application Discontinuation
- 2009-06-04 EC EC2009009385A patent/ECSP099385A/es unknown
- 2009-06-04 CO CO09057907A patent/CO6180428A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0718546A2 (pt) | 2013-11-19 |
MA30921B1 (fr) | 2009-11-02 |
CL2007003194A1 (es) | 2008-06-13 |
JP2010508370A (ja) | 2010-03-18 |
PE20121179A1 (es) | 2012-09-13 |
AU2007323465A1 (en) | 2008-05-29 |
TW200827326A (en) | 2008-07-01 |
EP2079463A1 (de) | 2009-07-22 |
CN101594857B (zh) | 2012-10-31 |
US20100048716A1 (en) | 2010-02-25 |
MY148758A (en) | 2013-05-31 |
AR063560A1 (es) | 2009-02-04 |
IL198470A0 (en) | 2010-02-17 |
CN101594857A (zh) | 2009-12-02 |
US8119841B2 (en) | 2012-02-21 |
TN2009000174A1 (en) | 2010-10-18 |
GT200900116A (es) | 2011-06-07 |
ECSP099385A (es) | 2009-07-31 |
MX2009004885A (es) | 2009-05-19 |
WO2008061622A1 (en) | 2008-05-29 |
RU2466982C2 (ru) | 2012-11-20 |
RU2009121651A (ru) | 2010-12-20 |
NO20092102L (no) | 2009-07-30 |
CO6180428A2 (es) | 2010-07-19 |
AU2007323465B2 (en) | 2011-08-04 |
KR20090083918A (ko) | 2009-08-04 |
CA2668828A1 (en) | 2008-05-29 |
NZ577320A (en) | 2012-01-12 |
PE20081157A1 (es) | 2008-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200902941B (en) | Crystalline forms of aliskiren hemifumarate | |
HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
PT2356090T (pt) | Formas cristalinas de fingolimod, hcl | |
IL205649A0 (en) | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof | |
IL196706A0 (en) | Crystalline forms of rapamycin analogs | |
IL192479A0 (en) | Method of inducing nucleation of a material | |
GB0608190D0 (en) | Method of purification | |
ZA200903971B (en) | Crystalline modification of fipronil | |
ZA200903970B (en) | Crystalline modification of fipronil | |
ZA200903967B (en) | Crystalline modification of fipronil | |
IL184945A0 (en) | Crystalline forms of pregabalin | |
ZA200903614B (en) | New crystalline forms | |
HK1135961A1 (en) | Crystalline potassium salt of lipoxin a4 analogs | |
ZA200903972B (en) | Crystalline modification of fipronil | |
PT1996542E (pt) | Sal nitrato de aliscireno | |
IL209325A0 (en) | Solid states of aliskiren free base | |
IL205451A0 (en) | Crystalline forms of tigecycline hydrochloride | |
IL195061A0 (en) | Crystalline forms of atorvastatin | |
IL200048A (en) | Solid forms of microbiocide | |
EP2160376A4 (de) | Neue kristalline formen von atovaquon | |
EP1993547A4 (de) | Arzneistoffvorstufen von benzochinolizin-2-carbonsäure | |
IL193025A0 (en) | Crystalline forms of ciclesonide | |
GB0619888D0 (en) | New polymorphic forms of pregabalin | |
IL195092A0 (en) | Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate | |
EP2017254A4 (de) | Kristallisationsverfahren |